Hofseth BioCare ASA (HBC.OL)
NOK 2.1
(0.95%)
NOK 2.1
(0.95%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 194.87 Million NOK | 58.42% |
| 2022 | 120.44 Million NOK | 37.47% |
| 2021 | 87.61 Million NOK | 26.52% |
| 2020 | 69.25 Million NOK | 2.17% |
| 2019 | 67.77 Million NOK | 11.59% |
| 2018 | 60.74 Million NOK | -48.73% |
| 2017 | 118.47 Million NOK | 486.4% |
| 2016 | 20.2 Million NOK | -63.36% |
| 2015 | 55.13 Million NOK | 178.91% |
| 2014 | 19.76 Million NOK | -68.59% |
| 2013 | 62.93 Million NOK | 141.92% |
| 2012 | 26.01 Million NOK | 2099.07% |
| 2011 | 1.18 Million NOK | 591.81% |
| 2010 | 171 Thousand NOK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 72.18 Million NOK | 54.34% |
| 2024 Q1 | 52.09 Million NOK | 13.53% |
| 2023 Q2 | 52.94 Million NOK | 18.26% |
| 2023 Q4 | 45.88 Million NOK | -7.74% |
| 2023 Q3 | 49.73 Million NOK | -6.05% |
| 2023 FY | 190.81 Million NOK | 58.42% |
| 2023 Q1 | 44.76 Million NOK | 33.2% |
| 2022 Q4 | 33.6 Million NOK | 11.21% |
| 2022 Q3 | 30.22 Million NOK | 16.99% |
| 2022 Q2 | 25.83 Million NOK | -16.08% |
| 2022 FY | 120.44 Million NOK | 37.47% |
| 2022 Q1 | 30.78 Million NOK | 18.03% |
| 2021 Q2 | 31.04 Million NOK | 84.38% |
| 2021 Q1 | 16.83 Million NOK | -26.97% |
| 2021 Q3 | 13.65 Million NOK | -56.01% |
| 2021 Q4 | 26.08 Million NOK | 90.96% |
| 2021 FY | 87.61 Million NOK | 26.52% |
| 2020 FY | 69.25 Million NOK | 2.17% |
| 2020 Q1 | 18.52 Million NOK | 66.24% |
| 2020 Q3 | 7.57 Million NOK | -62.29% |
| 2020 Q2 | 20.09 Million NOK | 8.49% |
| 2020 Q4 | 23.05 Million NOK | 204.21% |
| 2019 Q4 | 11.14 Million NOK | -61.8% |
| 2019 Q2 | 12.78 Million NOK | -12.93% |
| 2019 Q1 | 14.68 Million NOK | 1.43% |
| 2019 Q3 | 29.17 Million NOK | 128.21% |
| 2019 FY | 67.77 Million NOK | 11.59% |
| 2018 Q2 | 14.76 Million NOK | 0.0% |
| 2018 FY | 60.74 Million NOK | -48.73% |
| 2018 Q1 | 14.76 Million NOK | -44.07% |
| 2018 Q4 | 14.47 Million NOK | -14.43% |
| 2018 Q3 | 16.91 Million NOK | 14.54% |
| 2017 Q3 | 27.92 Million NOK | 407.23% |
| 2017 FY | 118.47 Million NOK | 486.4% |
| 2017 Q4 | 26.4 Million NOK | -5.44% |
| 2017 Q1 | 58.64 Million NOK | 1794.19% |
| 2017 Q2 | 5.5 Million NOK | -90.61% |
| 2016 Q4 | 3.09 Million NOK | -13.5% |
| 2016 FY | 20.2 Million NOK | -63.36% |
| 2016 Q2 | 8.17 Million NOK | 52.5% |
| 2016 Q1 | 5.35 Million NOK | -79.95% |
| 2016 Q3 | 3.57 Million NOK | -56.2% |
| 2015 Q3 | 16.63 Million NOK | 160.55% |
| 2015 Q4 | 26.72 Million NOK | 60.63% |
| 2015 FY | 55.13 Million NOK | 178.91% |
| 2015 Q1 | 5.38 Million NOK | -40.84% |
| 2015 Q2 | 6.38 Million NOK | 18.61% |
| 2014 FY | 19.76 Million NOK | -68.59% |
| 2014 Q4 | 9.1 Million NOK | 432.53% |
| 2014 Q3 | 1.7 Million NOK | -76.86% |
| 2014 Q2 | 7.38 Million NOK | 369.19% |
| 2014 Q1 | 1.57 Million NOK | -91.9% |
| 2013 Q1 | 10.11 Million NOK | 58.14% |
| 2013 Q2 | 7.92 Million NOK | -21.59% |
| 2013 Q3 | 25.47 Million NOK | 221.33% |
| 2013 Q4 | 19.42 Million NOK | -23.76% |
| 2013 FY | 62.93 Million NOK | 141.92% |
| 2012 Q1 | 1.56 Million NOK | 570.18% |
| 2012 Q3 | 11.49 Million NOK | 75.11% |
| 2012 Q4 | 6.39 Million NOK | -44.38% |
| 2012 FY | 26.01 Million NOK | 2099.07% |
| 2012 Q2 | 6.56 Million NOK | 320.2% |
| 2011 Q1 | 433.8 Thousand NOK | 389.06% |
| 2011 Q4 | 233.1 Thousand NOK | -1.23% |
| 2011 FY | 1.18 Million NOK | 591.81% |
| 2011 Q3 | 236 Thousand NOK | -15.71% |
| 2011 Q2 | 280 Thousand NOK | -35.45% |
| 2010 Q4 | 88.7 Thousand NOK | -20.52% |
| 2010 FY | 171 Thousand NOK | 0.0% |
| 2010 Q3 | 111.6 Thousand NOK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Arctic Bioscience AS | 33.75 Million NOK | -477.404% |
| Aqua Bio Technology ASA | 1.55 Million NOK | -12394.302% |
| ArcticZymes Technologies ASA | 118.93 Million NOK | -63.844% |
| BerGenBio ASA | 354 Thousand NOK | -54949.153% |
| PCI Biotech Holding ASA | 2.99 Million NOK | -6417.525% |
| Thor Medical ASA | - NOK | -Infinity% |
| Ultimovacs ASA | - NOK | -Infinity% |